scivent is proud to have the opportunity to offer courses with leading experts in the field of pharmaceutical R&D, financing, licensing and business development.

The two-day interactive courses shall provide a forum where state-of-the-art strategies are presented and discussed in smaller groups. The courses have been developed for 15–20 attendees.

Faculty Members

Aspiras, Mainz, Germany

Boston Consulting, Düsseldorf, Germany

Egon Zehnder International, Düsseldorf, Germany

Ernst & Young, Stuttgart, Germany

Maucher, Börjes & Kollegen, Freiburg i.Br., Germany

PCC Paul Charlton Consulting, Garmisch Patenkirchen, Germany

Perlitz Strategy Group, Mannheim, Germany

Ropes & Gray, Boston, USA

Additional Companies presenting

Business Angels Netzwerk Deutschland e.V.

Cap Gemini Ernst & Young

DVC Deutsche Venture Capital

Global Life Science Venture

Kirchhoff Consult

Paul Capital Partners

PricewaterhouseCoopers

Nextech Venture

Novartis Venture Fund

COURSE 1 MARCH 04 - 05, 2004

Global Deal Making: The Pitch

Paul Charlton, PCC Paul Charlton Consulting, Garmisch-Patenkirchen, Germany

COURSE 2 MARCH 08 - 09, 2004

Global Deal Making: The Negotiations

Paul Charlton, PCC Paul Charlton Consulting, Garmisch-Patenkirchen, Germany

COURSE 3 MARCH 15 - 16, 2004

Market Protection Licensing Strategies for Pharmaceutical and Biotechnology Companies

Manuel Kunst, Maucher, Börjes & Kollegen, Freiburg, Germany

Marc Rubenstein , Ropes & Gray, Boston USA

Gregory Glover, Ropes & Gray, Boston, USA

Bernhard Hertel, Garching Innovation GmbH, Munich, Germany

Gabriele Alt, European Patent Office, Munich, Germany

Marc Reinhardt, Cap Gemini Ernst & Young, Stuttgart, Germany

COURSE 4 MARCH 17 - 18, 2004

Comprehensive Deal Valuation and Portfolio Planning

Randolf Schrank , Perlitz Strategy Group, Mannheim, Germany

Matthias Litschke, Perlitz Strategy Group, Mannheim, Germany

Thomas Brennecke, Merckle GmbH, Ulm, Germany

Sven Rohmann, BioVisioN AG, Hannover, Germany

Representative from Pharma Industry

COURSE 5 MARCH 22 - 23, 2004

Mergers & Acquisitions and Valuation of Biotech Companies

Jakob Geyer, Ernst & Young, Frankfurt, Germany

Siegfried Bialojan, Ernst & Young, Mannheim, Germany

Christopher Klein, Ernst & Young, Frankfurt, Germany

Ulrich Moser, Ernst & Young, Stuttgart, Germany

Manuel Bauer, Ernst & Young, Munich, Germany

Stefan Weber, Biofrontera Pharmaceuticals, Cologne, Germany

Carsten Dehning, DeveloGen, Göttingen, Germany

COURSE 6 March 25 - 26, 2004

Human Resources: Developing the Right Strategy – Building the Right Team

Axel Heinemann, Boston Consulting Group, Düsseldorf, Germany

Johannes von Schmettow, Egon Zehnder International, Düsseldorf, Germany

COURSE 7 March 29 - 30, 2004

Innovative Financing

Volker Fitzner, PricewaterhouseCoopers, Frankfurt, Germany

Thomas Taapken, DVC Deutsche Venture Capital, Munich, Germany

Rudolf Gygax, Novartis Venture Fund, Basel, Switzerland

Klaus Breiner, Global Life Science Ventures, Munich, Germany

Martin Austin, Paul Capital Partners, Basel, Switzerland

Alfred Scheidegger, Nextech Venture, Zürich, Switzerland

Ute Günther, Business Angels Netzwerk e.V., Essen, Germany

Petra Nix, Kirchhoff Consult AG, Luzern, Switzerland

COURSE 8 April 01 - 02, 2004

Project Management for Pharma- and Biotech Industry

Harald O. Borbe, Aspiras, Mainz, Germany

Anita Dürr, Aspiras, Mainz, Germany

Cathrin Pauly, Aspiras, Mainz, Germany

Evelyn Orbach-Yliruka, EOY Zukunftsmanagement, Talheim, Germany